US10493094B2ActiveUtilityA1

Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells

85
Assignee: GEL E INCPriority: Mar 13, 2013Filed: Feb 27, 2017Granted: Dec 3, 2019
Est. expiryMar 13, 2033(~6.7 yrs left)· nominal 20-yr term from priority
A61K 31/722A61K 38/39A61K 31/717A61K 31/734
85
PatentIndex Score
4
Cited by
256
References
18
Claims

Abstract

A hemostatic putty for treatment of a variety of wounds topographies, including but not limited to highly three dimensional wounds, for example gunshot wounds and impalements, is disclosed. The putty is comprised of a matrix polymer weakly crosslinked or not crosslinked such that a viscoelastic matrix is formed. The viscoelastic nature of the putty is tunable by the composition and enables the putty to conform to a variety of wound topographies. Likewise, a hemostatic polymer, for example chitosan or hydrophobically modified chitosan, is included in this matrix to impart hemostatic properties and tissue adhesive on the putty. The hemostatic polymers disclosed prevent microbial infection and are suitable for oxygen transfer required during normal wound metabolism.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A putty, comprising:
 a hemostatic biopolymer selected from hydrophobically modified alginate and hydrophobically modified gelatin, 
 a secondary polymer, and wherein the secondary polymer is polyvinyl alcohol 
 an ionic crosslinker, and 
 a solvent. 
 
     
     
       2. The putty of  claim 1 , wherein the hydrophobically modified biopolymer comprises hydrophobic substituents covalently attached to the biopolymer. 
     
     
       3. The putty of  claim 2 , wherein the hydrophobic substituents comprise from eight to eighteen carbon atoms. 
     
     
       4. The putty of  claim 3 , wherein the hydrophobic modification is of 1 to 100 moles of hydrophobic substituent per 1 mole of biopolymer. 
     
     
       5. The putty of  claim 1 , wherein the hydrophobically modified alginate is selected from the group consisting of sodium alginate, potassium alginate, magnesium alginate, calcium alginate, aluminum alginate. 
     
     
       6. The putty of  claim 1 , wherein the polyvinyl alcohol is present in a concentration of between 5 wt % and 15 wt %. 
     
     
       7. The putty of  claim 6 , wherein the polyvinyl alcohol has a molecular weight in of between 50,000 Da and 300,000 Da. 
     
     
       8. The putty of  claim 6 , wherein the polyvinyl alcohol has a molecular weight in of between 125,000 Da and 140,000 Da. 
     
     
       9. The putty of  claim 6 , wherein the polyvinyl alcohol is hydrolyzed in a range of 70% to 100%. 
     
     
       10. The putty of  claim 1 , wherein the crosslinker is present in a concentration of between 0.1 wt % and 1.0 wt %. 
     
     
       11. The putty of  claim 1 , wherein the hemostatic biopolymer is present in a concentration of between 0.1 wt % and 3.0 wt %. 
     
     
       12. The putty of  claim 1 , wherein the composition of matter is capable of providing a compressing force of between 5 and 15 N, 15 and 30 N, or 0.1 and 5N. 
     
     
       13. The putty of  claim 1 , where in the crosslinker is a borate salt. 
     
     
       14. The putty of  claim 13 , wherein the borate salt is selected from the group consisting of sodium tetraborate decahydrate, sodium peroborate, and sodium metaborate. 
     
     
       15. The putty of  claim 1 , further comprising a water soluble reagent. 
     
     
       16. The putty of  claim 15 , wherein the water soluble reagent selected from the group consisting of human thrombin, bovine thrombin, recombinant thrombin, and human fibrinogen. 
     
     
       17. The putty of  claim 1 , further comprising a reagent selected from the group consisting of fibrinogen, factor VIIa, Factor XIII. 
     
     
       18. The putty of  claim 1 , further comprising a reagent that prevent microbial infections.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.